In Vitro Drug Screening Identifies Treatment Vulnerabilities in Brain Metastasis Cultures

Overview

This study developed a clinically compatible in vitro drug screening platform using patient-derived brain metastasis (BM) tumor spheroid cultures. Integration of drug sensitivity data with genetic profiling revealed personalized therapeutic vulnerabilities, highlighting potential treatment options for BM patients.

Background

Brain metastases occur in approximately 20–25% of patients with metastatic cancers such as lung, breast, kidney, colon carcinomas, and melanoma, and are ten times more frequent than primary brain tumors. Despite advances in primary tumor treatments and novel therapies like stereotactic radiosurgery and immune checkpoint inhibitors, median survival remains limited. The heterogeneity and prior treatment exposure of BM patients complicate treatment selection, underscoring the need for personalized approaches. In vitro drug screening combined with molecular profiling may enhance individualized therapy strategies for these patients.

Data Highlights

Primary tumor spheroid cultures were established from freshly resected BM specimens and cultured under defined conditions. Gene-panel next-generation sequencing was performed on tumor tissue and spheroid cultures to identify mutations in cancer-associated genes. Cell viability after drug exposure was assessed using the CellTiter-Glo luminescent assay in high-throughput 1536-well plate format, enabling quantitative measurement of drug sensitivity across multiple agents.

Key Findings

• Primary BM tumor spheroid cultures can be reliably established and maintained in vitro, preserving tumor characteristics.
• Gene-panel NGS identified actionable mutations in BM samples, facilitating integration of molecular data with drug response.
• High-throughput drug screening revealed heterogeneous drug sensitivities among individual BM cultures, indicating variable therapeutic vulnerabilities.
• Combining genetic alterations with drug response data enabled identification of personalized treatment options for BM patients.
• The platform is compatible with clinical workflows, supporting its potential use in personalized medicine for BM management.

Clinical Implications

This in vitro drug screening platform offers a promising tool to guide personalized therapy selection for patients with brain metastases by identifying individual tumor vulnerabilities. Integration of molecular profiling with functional drug sensitivity testing may improve treatment efficacy and overcome resistance in this complex patient population. Adoption of such approaches could enhance clinical decision-making and patient outcomes.

Conclusion

The study demonstrates that patient-derived BM spheroid cultures combined with high-throughput drug screening and genetic analysis can uncover personalized therapeutic vulnerabilities. This approach holds potential to advance precision medicine in the management of brain metastases.

References

1. Nolte et al. -- Establishment of primary tumor spheroid cultures
2. Surveillance Epidemiology and End Results database -- BM survival statistics
3. Ion AmpliSeq™ Cancer Hotspot Panel v2 -- Gene panel details